Sidley represented Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) (“Zai Lab”) on its US$230 million equity offering of American depositary shares (“ADSs”) listed on the Nasdaq Global Market. Goldman Sachs (Asia) L.L.C., Jefferies LLC, and Leerink Partners LLC acted as joint underwriters for the offering. The offering involved the allotment and issuance of new ordinary shares of Zai Lab as the underlying securities of the ADSs.

Zai Lab is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. Zai Lab is focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease.

The Sidley team, which advised Zai Lab on Hong Kong regulatory aspects of the transaction, was led by partner Claudia Yu (Hong Kong), with the support of counsel Eva Tsui, senior managing associate Ammo Chan, and trainee solicitor Wincy Yim. Partner Sara M. von Althann (Washington D.C.), provided advice on SEC regulatory matters.

Sidley’s China Life Sciences practice is an integrated part of the firm’s Global Life Sciences practice, which has more than 200 dedicated lawyers worldwide. It is the only Band One firm ranked by Chambers Greater China Region/APAC in life sciences for 16 consecutive years. Sidley advises clients along the full business lifecycle, from company formation, corporate governance (including incentive plans), and compliance operations for the startup phase; to product collaboration, licensing, commercialization, and regulatory filing matters in the business development phase; to initial public offerings, refinancings, and debt issuances in the capital-raising phase; to further significant transactions including domestic and cross-border mergers and acquisitions, asset restructurings, and privatizations, as well as dispute resolution.